• Explore /
  • Poster
  • / Phase 1b/II study of cancer stemness inhibitor napabucasin (BBI-608) in combination with FOLFIRI +/- bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts).

Phase 1b/II study of cancer stemness inhibitor napabucasin (BBI-608) in combination with FOLFIRI +/- bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts).

Abstract Poster

Authors

null

Johanna C. Bendell

Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN

Johanna C. Bendell , Joleen Marie Hubbard , Bert H. O'Neil , Derek J. Jonker , Alexander Starodub , James D. Peyton , Henry C. Pitot , Thorvardur Ragnar Halfdanarson , Benjamin Rolland Nadeau , John D. Zubkus , Bamidele Adesunloye , William Jeffery Edenfield , Youzhi Li , Wei Li , Axel Grothey , Laura Borodyansky , Chiang Li

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

NCT02024607

Citation

J Clin Oncol 35, 2017 (suppl; abstr 3529)

DOI

10.1200/JCO.2017.35.15_suppl.3529

Abstract #

3529

Poster Bd #

152

Abstract Disclosures

Similar Posters

First Author: Johanna C. Bendell

First Author: Axel Grothey

First Author: Bert H. O'Neil

First Author: Bassel F. El-Rayes